SWN
42
-4
NVDA
59
5
GS
70
4
AVY
71
-4
EQIX
45
-2
PNW
49
3
O
37
-5
AEP
56
-3
BAC
45
-5
TXT
72
-3
HAS
42
-6
ECL
64
-6
AME
60
-3
OMC
48
-3
SPG
56
-7
ORLY
58
-3
KEY
43
-3
PVH
59
-5
JNJ
26
-4
PGR
65
-4
SWN
42
-4
NVDA
59
5
GS
70
4
AVY
71
-4
EQIX
45
-2
PNW
49
3
O
37
-5
AEP
56
-3
BAC
45
-5
TXT
72
-3
HAS
42
-6
ECL
64
-6
AME
60
-3
OMC
48
-3
SPG
56
-7
ORLY
58
-3
KEY
43
-3
PVH
59
-5
JNJ
26
-4
PGR
65
-4
Financhill
Back

Keros Therapeutics Quote, Financials, Valuation and Earnings

Elon's New AI Device is About to Shock the World

Click here to see the details because a lot of people could get rich from this new invention.
Sell
25

KROS
Keros Therapeutics

Last Price:
45.02
Seasonality Move:
4.22%

7 Day Trial

ALL ACCESS PASS

$ 7

Jeff Bezos's Plan Exposed

And for investors who get in now profits could be massive - click here for full story.

Keros Therapeutics Price Quote

$45.02
-0.63 (-1.38%)
(Updated: June 26, 2024 at 1:40 PM ET)

Keros Therapeutics Key Stats

Sell
25
Keros Therapeutics (KROS) is a Sell
Day range:
$45.12 - $47.20
52-week range:
$27.02 - $73.00
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
3.63%
Volume:
245.7K
Avg. volume:
329.4K
1-year change:
10.05%
Market cap:
$1.6B
Revenue:
$151K
EPS:
$-5.15

How Much Does Keros Therapeutics Make?

Data Unavailable

Is Keros Therapeutics Growing As A Company?

Data Unavailable

Keros Therapeutics Stock Price Performance

What Is Keros Therapeutics 52-Week High & Low?

Keros Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Keros Therapeutics?

Is Keros Therapeutics Cash Flow Positive?

  • What Is KROS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$134.8M
  • What Is Keros Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $228.1M
  • What Is Keros Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$2.3M

Keros Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    KROS return on invested capital is -45.46%
  • What Is Keros Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -41.68%
  • What Is KROS Return On Equity?
    ROE is a measure of profitability and is -45.46%

Keros Therapeutics Earnings Date & Stock Price

Keros Therapeutics Competitors

  • Who Are Keros Therapeutics's Competitors?
    Below is a list of companies who compete with Keros Therapeutics or are related in some way:
    • ADMA Biologics Inc (ADMA)
    • Alnylam Pharmaceuticals Inc (ALNY)
    • Biomarin Pharmaceutical Inc (BMRN)
    • PTC Therapeutics Inc (PTCT)
    • Sarepta Therapeutics Inc (SRPT)

Keros Therapeutics Dividend Yield

Data Unavailable

Keros Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 9.28%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 9
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 90.10
Upside from Last Price: 97.37%

Major Shareholders

  • How many KROS shares are owned by institutional investors?
    47.9M KROS shares are owned by institutional investors
  • How many KROS shares are owned by insiders?
    372.2K KROS shares are owned by insiders